<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE paragraph
  PUBLIC "-//IFRS//DTD DITA Paragraph//EN" "../../../../DocTypes/com.ifrs.doctype/dtd/paragraph.dtd">
<paragraph id="IAS41_B39" base="SL33541"><paranum>B39</paranum><prolog><data name="standard_number" value="IASÂ 41"/><data name="paranum" value="B39"/></prolog><body><p id="IAS41_P0818">Some commentators on the DSOP and E65 argued that fair value changes should be included directly in equity, through the statement of changes in equity, until realised, arguing that: </p><ol id="IAS41_L0033" base="SL155374" type="lower-alpha"><li><li_value>(a)</li_value> <p id="IAS41_P0819" base="SL155376">the effects of biological transformation cannot be measured reliably and, therefore, should not be reported as income;</p></li><li><li_value>(b)</li_value> <p id="IAS41_P0820" base="SL155378">fair value changes should only be included in net profit or loss when the earnings process is complete;</p></li><li><li_value>(c)</li_value> <p id="IAS41_P0821" base="SL155380">recognition of unrealised gains and losses in net profit or loss increases volatility of earnings;</p></li><li><li_value>(d)</li_value> <p id="IAS41_P0822" base="SL155382">the results of biological transformation may never be realised, particularly given the risks to which biological assets are exposed; and</p></li><li><li_value>(e)</li_value> <p id="IAS41_P0823" base="SL155384">it is premature to require recognition of fair value changes in net profit or loss, until performance reporting issues are resolved.</p></li></ol></body></paragraph>